Preregistration •
Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism –
Multidisciplinary Association for Psychedelic Studies (MAPS),
Lykos Therapeutics Phase 3 •
HLP003 (HLP-003; CYB003; deuterated psilocybin analogue; deuterated psilocin; deupsilocin) – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – major depressive disorder, alcoholism, psychiatric disorders –
Helus Pharma (Cybin) •
Ketamine (AWKN-001, AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism, binge-eating disorder, gambling, impulse control disorders, obsessive–compulsive disorder – Awakn Life Sciences •
Ketamine (HTX-100; NRX-100) – ionotropic glutamate NMDA receptor antagonist – suicidal ideation, mental disorders – NRx Pharmaceuticals •
Lysergic acid diethylamide (LSD; lysergide; DT120; DT-120; MM120; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder, pain –
Definium Therapeutics (MindMed) •
Lysergic acid diethylamide (LSD; lysergide; MB-22001/MB22001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, existential distress in cancer patients – MindBio Therapeutics •
Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, borderline personality disorder –
Usona Institute Phase 2 •
(R)-Midomafetamine ((
R)-MDMA; (
R)-methylenedioxymetamfetamine; MM-402) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – pervasive child development disorders/autism spectrum disorder – Definium Therapeutics (MindMed) •
Arketamine ((
R)-ketamine; PCN-101) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders –
ATAI Life Sciences •
Blixeprodil (GM-1020; (
R)-4-fluorodeschloroketamine; (
R)-4-FDCK) – orally active NMDA receptor receptor antagonist – major depressive disorder, bipolar depression, depressive disorders –
Gilgamesh Pharmaceuticals •
Bretisilocin (GM-2505; 5F-MET; 5-fluoro-
N-methyl-
N-ethyltryptamine) – serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor antagonist, psychedelic hallucinogen, and serotonin releasing agent – major depressive disorder – Gilgamesh Pharmaceuticals •
Dimethyltryptamine (DMT; BMND-01/BMND01, BMND-02/BMND02, BMND-03/BMND03) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, fibromyalgia, substance-related disorders – Biomind Labs •
Esketamine (CLE-100) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, bipolar depression – Clexio Biosciences •
Ketamine (Ereska; IN ketamine; ketamine IN; intranasal ketamine; intranasal racemic ketamine; PMI-100, PMI-150, SLS-002, TUR-002) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, suicidal ideation, acute pain, cancer pain – Seelos Therapeutics •
Ketamine extended-release (R-107, R107) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Douglas Pharmaceuticals •
Ketamine prolonged-release oral (KET-01) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders, neuropathic pain – Ketabon •
Ketamine/temsirolimus (FREE001) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and mTOR inhibitor combination – major depressive disorder – Freedom Biosciences •
Mebufotenin (5-MeO-DMT; BPL-002, BPL-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Beckley Psytech •
Mebufotenin (5-MeO-DMT; BMND-05/BMND05, BMND-08/BMND08) – non-selective serotonin receptor agonist and psychedelic hallucinogen – Alzheimer's disease, pain – Biomind Labs •
Mebufotenin (5-MeO-DMT; GH001/GH-001; GH002/GH-002; GH003/GH-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – GH Research •
Midomafetamine/citalopram (MDMA/citalopram) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen followed by a selective serotonin reuptake inhibitor – post-traumatic stress disorder –
Tactogen •
MSP-1014 (psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Mindset Pharma, Otsuka America Pharmaceutical • Non-racemic
midomafetamine (MDMA; "ecstasy"; 70–80% (
R)-MDMA, 20–30% (
S)-MDMA) – social anxiety in autism spectrum disorder – PharmAla Biotech •
OSU-6162 (PNU-9639; PNU-96391; PNU-96391A) – non-hallucinogenic serotonin 5-HT2A receptor partial agonist, dopamine D2 receptor partial agonist, and sigma σ1 receptor ligand (so-called "monoaminergic stabilizer") – bipolar depression, chronic fatigue syndrome, depressive disorders, stroke, subarachnoid hemorrhage, Parkinson's disease – Carlsson Research AB, Pfizer •
Psilocin – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorder – Psyence BioMed •
Psilocybin (low-dose; APEX-52 / 90) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anxiety disorders – Apex Laboratories •
Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – post-traumatic stress disorder, anxiety disorders, depressive disorders, headache, substance-related disorders –
Mydecine •
Psilocybin (PEX-010/PEX010) – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorders, alcoholism, depressive disorders, anxiety disorders – Filament Health •
Psilocybin (PFN™; TRP-8802, TRP-8803, TRP-8804, TRYP-0082) – non-selective serotonin receptor agonist and psychedelic hallucinogen – binge-eating disorder, fibromyalgia, irritable bowel syndrome, cancer, complex regional pain syndrome, pain – Tryp Therapeutics •
Psilocybin (Psi-GAD; PSX-001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Incannex •
Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, Alzheimer's disease, irritable bowel syndrome, Parkinson's disease, pervasive child development disorders, panic disorder – Nobilis Therapeutics •
Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist, other actions – leishmaniasis, opioid-related disorders, substance-related disorders – Definium Therapeutics (MindMed)
Phase 1/2 •
Dimethyltryptamine (DMT; SPL-026) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Small Pharma, Helus Pharma (Cybin) •
Dimethyltryptamine/harmine (DMT/harmine; RE01) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – generalized anxiety disorder – reconnect Labs •
Psilocybin infusion (ELE-101, ELE-Psilo, ELE-Psilo+) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder –
Eleusis, Beckley Psytech
Phase 1 •
2-Bromo-LSD (bromolysergide; BOL-148; NYPRG-101) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – cluster headache, migraine – Ceruvia Lifesciences •
BMND07 (BMND-07; dimethyltryptamine or 5-MeO-DMT combination drug) – non-selective serotonin receptor agonist, serotonergic hallucinogen, and other actions combination – major depressive disorder – Biomind Labs •
Dimethyltryptamine (DMT; AP-188; IV DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – stroke – Algernon Neuroscience •
Dimethyltryptamine (DMT; VLS-01; buccal DMT film) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Viridia Life Sciences •
Esketamine ((
S)-ketamine;
S-ketamine; AWKN-002) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism – Awakn Life Sciences •
Ketamine oral (Keticap) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – mood disorders – Neurocentrx Pharma •
Ketanserin – serotonin 5-HT2A and α1-adrenergic receptor antagonist – hallucinogen antidote – Definium Therapeutics (MindMed) •
Lys-MDA – methylenedioxyamphetamine (MDA) prodrug (serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen) – unknown – Definium Therapeutics (MindMed),
MiHKAL •
Lys-MDMA – midomafetamine (MDMA) prodrug (serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen) – unknown – Definium Therapeutics (MindMed), MiHKAL •
Mescaline (JOUR-5700) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism – Journey Colab •
Noribogaine (DMX-1001) – various actions – alcohol use disorder – DemeRx •
SPL028 (D2-DMT; α,α-dideutero-DMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – Helus Pharma (Cybin), Small Pharma •
Zalsupindole (DLX-001; DLX-1; AAZ; AAZ-A-154) – non-hallucinogenic serotonin 5-HT2A receptor agonist – CNS disorders, major depressive disorder –
Delix Therapeutics Clinical phase unknown •
Eplivanserin/volinanserin – fixed-dose combination of
eplivanserin (serotonin 5-HT2A receptor antagonist) and
volinanserin (serotonin 5-HT2A receptor antagonist) – hallucinogen antidote – Terran Biosciences
Preclinical •
2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – cluster headache, major depressive disorder, neuropathic pain, post-traumatic stress disorders – Transcend Biodynamics, BetterLife Pharma •
2-Fluorodeschloroketamine (2-FDCK) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Clearmind Medicine •
3-Methylmethcathinone (3-MMC; metaphedrone) – serotonin, norepinephrine, and dopamine releasing agent and entactogen – dyskinesias – Clearmind Medicine •
AKO-001 (dimethyltryptamine/specific plant bioactive; DMT/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – stroke – Akome Biotech •
AKO-002 (psilocybin-based formulation; psilocybin/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – Alzheimer's disease – Akome Biotech •
AKO-003 (ketamine-based psychedelic formulation; ketamine/specific plant bioactive) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and "specific plant bioactive" combination – major depressive disorder – Akome Biotech •
AKO-004 (dimethyltryptamine/specific plant bioactive; DMT/specific plant bioactive) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and "specific plant bioactive" combination – Parkinson's disease – Akome Biotech •
APA-01 (PharmAla-1) – entactogen (predicted monoamine transporter and serotonin 5-HT2 receptor modulator) – unknown – PharmAla Biotech •
BMB-201 (BMB-A39a prodrug) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist and psychoplastogen – generalized anxiety disorder, pain –
Bright Minds Biosciences •
BMB-202 – selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – depressive disorders, post-traumatic stress disorder – Bright Minds Biosciences •
Dimethyltryptamine (DMT; Triptax) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – Biomind Labs •
DLX-159 (tryptamine derivative) – undisclosed mechanism of action, serotonin 5-HT2B receptor antagonist, and psychoplastogen – major depressive disorder, psychiatric disorders – Delix Therapeutics •
EB-003 – non-hallucinogenic serotonin receptor agonist and psychoplastogen – anxiety disorders, depressive disorders – Enveric Biosciences •
EGX-A – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Entheogenix Biosciences •
EGX-B – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Entheogenix Biosciences •
EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders – Equulus Therapeutics •
GM-3009 (ibogaine analogue(s); GMX-3009) – various actions – opioid-related disorders, post-traumatic stress disorder, traumatic brain injury – Gilgamesh Pharmaceuticals •
GM-5022 – undefined mechanism of action (non-hallucinogenic psychoplastogen) – depressive disorders, anxiety disorders, neurological disorders – Gilgamesh Pharmaceuticals •
KB-128 – serotonin 5-HT2C receptor G protein-biased agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist – alcoholism – Küleon Bioscience (Psilosterics) •
Ibogaine – various actions and hallucinogen – CNS disorders, neuropathic pain, traumatic brain injury – MINDCURE •
Ibogaine/magnesium (SON-001) – combination of
ibogaine (various actions/hallucinogen) and
magnesium (mineral/cardioprotective agent) – Soneira Bio – traumatic brain injury and associated disabilities • Ibogaine derivatives - Terran Biosciences – various actions and potential hallucinogens – neurological disorders, psychiatric disorders – Terran Biosciences •
ITI-1549 – non-hallucinogenic serotonin 5-HT2A receptor agonist, serotonin 5-HT2B receptor antagonist, and psychoplastogen – psychiatric disorders – Intra-Cellular Therapies •
Ketamine subcutaneous (BB-106/BB106) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – acute pain, mental disorders – Bexson Biomedical • Long-acting MDMA prodrug (long-acting midomafetamine prodrug) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – neurological disorders, psychiatric disorders – Terran Biosciences •
LPH-5 (novel phenethylamine) – selective serotonin 5-HT2A receptor partial agonist and psychedelic hallucinogen – major depressive disorder – Lophora, Beckley Psytech •
Lysergic acid diethylamide (LSD; lysergide) – non-selective serotonin receptor agonist and psychedelic hallucinogen – neurological disorders, psychiatric disorders – Delix Therapeutics •
MBDB – serotonin and norepinephrine releasing agent, weak serotonin 5-HT1 and 5-HT2 receptor ligand, and entactogen – autism – PharmAla Biotech •
Mebufotenin (5-MeO-DMT; LSR-1019) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, psychiatric disorders – Lusaris Therapeutics •
Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – anxiety disorders, depressive disorders, post-traumatic stress disorder, substance-related disorders – PharmaTher, Revive Therapeutics •
MSP-4018 – serotonin 5-HT1A and 5-HT2A receptor agonist and psychedelic hallucinogen (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical •
MSP-4019 – undefined mechanism of action (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical •
MSP-4020 – undefined mechanism of action (5-MeO-DMT- and DMT-inspired drug) – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical •
MYCO-007 – undefined mechanism of action and short-acting MDMA-like entactogen – undefined indication – Mydecine •
Norbaeocystin – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – mental disorders – PsyBio Therapeutics •
PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – depressive disorders, mood disorders, neurodegenerative disorders, substance-related disorders – Psilera •
PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – depressive disorders, mood disorders, neurodegenerative disorders, substance-related disorders – Psilera •
PSIL-006 – non-hallucinogenic serotonin 5-HT2A and 5-HT6 receptor partial agonist – frontotemporal dementia – Psilera •
PSIL-020 – non-hallucinogenic serotonin 5-HT6 receptor agonist – undisclosed – Psilera •
Psilocin (PLZ-1015) – non-selective serotonin receptor agonist and psychedelic hallucinogen – pervasive child development disorders – Pilz Bioscience •
RE245 (RE-245) – non-hallucinogenic serotonin receptor agonist and psychoplastogen – undisclosed – Reunion Neuroscience • Research programme: hydroxynorketamine derivatives - Spirify Pharma – amino acid modulators and serine protease modulators – depressive disorders, pain – Spirify Pharma • Research programme: Ibogaine analogues - Gilgamesh Pharmaceuticals (GM-300X) – various actions – opioid-related disorders – Gilgamesh Pharmaceuticals • Research programme: mental disorder therapeutics - Cybin (Deuterated DMT series - Cybin) – serotonin receptor modulators and psychedelic hallucinogens – mental disorders – Small Pharma, Helus Pharma (Cybin) • Research programme: micro-dose serotonergics - Gilgamesh Pharmaceuticals – serotonin receptor agonists – attention-deficit hyperactivity disorder, major depressive disorder – Gilgamesh Pharmaceuticals • Research programme: non-hallucinogenic psychedelic therapeutics - Intra-Cellular Therapies (ITI-1500) – undefined mechanism of action – psychiatric disorders – Intra-Cellular Therapies • Research programme: psilocin derivatives - Enveric Biosciences – serotonin 5-HT2A receptor agonists and potential psychedelic hallucinogens – mental disorders – Enveric Biosciences • Research programme: psilocin prodrugs and derivatives - Terran Biosciences – serotonin 5-HT2A receptor agonists and psychedelic hallucinogens – neurological disorders, psychiatric disorders – Terran Biosciences • Research programme: psychedelic and empathogenic compounds - Terran Biosciences – serotonin receptor modulators – neurological disorders, psychiatric disorders – Terran Biosciences • Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism and psychedelic hallucinogens – alcoholism, anxiety disorders, depressive disorders, neurodegenerative disorders – Psilera • Research programme: psychedelic-based therapeutics - Clearmind Medicine/SciSparc – undefined mechanism of action – metabolic disorders, obesity, psychiatric disorders – Clearmind Medicine, SciSparc • Research programme: psychedelic microneedle patch - PharmaTher – undefined mechanism of action – neurological disorders, neuromuscular disorders, pain, psychiatric disorders – PharmaTher • Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders – Collaborations Pharmaceuticals • Research programme: serotonin 2A receptor agonists - Bright Minds Biosciences – serotonin 5-HT2A receptor agonists – major depressive disorder, post-traumatic stress disorder – Bright Minds Biosciences • Research programme: serotonin 2A/C receptor agonists - Bright Minds Biosciences – serotonin 5-HT2A and 5-HT2C receptor agonists – pain – Bright Minds Biosciences • Research programme: small tryptamine derivatives - Marvel Biosciences (non-hallucinogenic neuroplasticity program - Marvel Biosciences) – adenosine A2A receptor antagonists – depressive disorders – Marvel Biosciences • Research programme: SPL 029 series - Cybin (Oral DMT series - Cybin; SPL029) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders – Small Pharma, Helus Pharma (Cybin) • Serotonin 5-HT2 receptor agonists - Cybin – serotonin 5-HT2 receptor agonists (phenethylamines) – neurological disorders, psychiatric disorders – Helus Pharma (Cybin) •
Tabernanthalog (TBG; DLX-007; DLX-7) – non-hallucinogenic serotonin 5-HT2A receptor agonist – CNS disorders – Delix Therapeutics •
TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcohol use disorder, anorexia, binge-eating disorder – Tactogen •
TACT523 – undefined mechanism of action – alcohol use disorder, anorexia, binge-eating disorder – Tactogen •
TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen – major depressive disorder, post-traumatic stress disorder – Transneural Therapeutics, CaaMTech •
XYL-1001 (PSYLO-1001; PSYLO-100X) – non-hallucinogenic serotonin 5-HT2A and 5-HT6 receptor modulator and psychoplastogen – mental disorders – Psylo/Xylo
Research •
AM-1004 – undefined mechanism of action (short-acting psychoactive/entactogen combination) – major depressive disorder – Arcadia Medicine •
ASR-3001 (5-MeO-iPALT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – psychiatric disorders – Alexander Shulgin Research Institute •
Baeocystin (PLZ-1019) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – pervasive developmental disorders in children – Pilz Bioscience •
Bufotenin (bufotenine) – non-selective serotonin receptor agonist and psychedelic hallucinogen – undisclosed – Usona Institute •
HLP005 (HLP-005; CYB005; deuterated phenethylamine derivative) – undefined mechanism of action ("non-hallucinogenic doses") – psychiatric disorders – Helus Pharma (Cybin) •
Ibogaine – various actions – anorexia nervosa, neurological disorders, substance-related disorders – Biomind Labs •
LSR-3000 – undefined mechanism of action (tryptamine serotonergic neuroplastogen) – neurological disorders – Lusaris Therapeutics •
Lysergic acid diethylamide (LSD; lysergide; LSD-CUREfilm) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders – CURE Pharmaceutical •
Mebufotenin (5-MeO-DMT; LSR-2000) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Lusaris Therapeutics •
Mescaline (BMND-04/BMND04) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders, neurological disorders – Biomind Labs •
Midomafetamine (MDMA; "ecstasy"; MDMA-CUREfilm) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – mental disorders – CURE Pharmaceutical •
MYCO-002 – undefined mechanism of action and MDMA-like entactogen – mental disorders – Mydecine •
MYCO-004 (patch-delivered tryptamine compound) – undefined mechanism of action and psychedelic hallucinogen – smoking withdrawal, substance-related disorders – Mydecine •
N-Methyltryptamine (NMT; monomethyltryptamine) – undefined mechanism of action and psychedelic hallucinogen – unspecified – Core One Labs • Noribogaine derived therapeutic – various actions – opioid-related disorders – Definium Therapeutics (MindMed), Nextage Therapeutics •
Norpsilocin (PLZ-1017) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – pervasive developmental disorders in children – Pilz Bioscience •
PSYLO-5001 (Psylo-5001) – non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen – mental disorders – Psylo/Xylo • Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics – various actions and potential hallucinogens – opioid-related disorders – Definium Therapeutics (MindMed), Nextage Therapeutics • Research programme: lysergic acid diethylamide derivatives - Enveric Biosciences – serotonin 5-HT2A receptor agonists – mental disorders, neurological disorders, psychotic disorders – MagicMed Industries, Enveric Biosciences • Research programme: mescaline derivatives - Enveric Biosciences – serotonin 5-HT2 receptor agonists – mental disorders, neurological disorders – MagicMed Industries, Enveric Biosciences • Research programme: non-hallucinogenic psychedelic therapeutics - Sintalica Bioscience/University of Messina – undefined mechanism of action and non-hallucinogenic tryptamine serotonergic agents – Sintalica Bioscience, University of Messina • Research programme: psychiatric disorder therapies (neuroplastogens) - AbbVie/Gilgamesh Pharmaceuticals – undefined mechanism of action – psychiatric disorders – AbbVie, Gilgamesh Pharmaceuticals • Research programme: non-hallucinogenic psychiatric therapies - Daiichi Sankyo/Psylo – undefined mechanism of action – mental disorders – Daiichi Sankyo, Psylo/Xylo • Research programme: non-tryptamine psychedelic small molecules - Otsuka America Pharmaceutical – serotonin receptor modulators – neurological disorders, psychiatric disorders – Mindset Pharma, Otsuka America Pharmaceutical • Research programme: psychedelic and empathogenic therapeutics - COMPASS Pathways – undefined mechanism of action – mental disorders – COMPASS Pathways, MiHKAL • Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanism of action – depressive disorders, mental disorders, pain, post-traumatic stress disorder, substance-related disorders – Bexson Biomedical • Research programme: psychedelic therapeutics - COMPASS Discovery Center – serotonin 5-HT2A receptor modulators – mental disorders – COMPASS Discovery Center, COMPASS Pathways • Research programme: tryptamine analog therapeutics - Diamond Therapeutics – serotonin receptor modulators – Diamond Therapeutics •
SPT-348 – serotonin receptor modulator and non-hallucinogenic psychoplastogen (prodrug of
2-bromo-LSD) – mood disorders, depression and anxiety, neuropsychiatric disorders – Seaport Therapeutics ==Not under development==